Higher values indicate aggressive inorganic growth strategies, while lower values suggest a focus on organic growth or a pause in M&A activity.
The total value of goodwill recognized on the balance sheet resulting from business acquisitions completed during the re...
Standard metric for companies pursuing growth through strategic acquisitions.
other_goodwill_acquired_during_period| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
|---|---|---|---|---|---|---|---|---|
| Corporate | — | — | $0.00 | $0.00 | $0.00 | — | — | — |
| International | — | — | $0.00 | $4.00M | $0.00 | — | — | — |
| Medical-Surgical Solutions | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| North American Pharmaceutical | $250.00K | $250.00K | — | — | — | — | $0.00 | $0.00 |
| Oncology & Multispecialty | $0.00 | $0.00 | — | — | — | — | $28.00M | — |
| Prescription Technology Solutions | — | — | $0.00 | — | $39.00M | — | — | — |
| U.S. Pharmaceutical | — | — | $0.00 | $1.00M | $1.24B | — | — | — |
| Total | — | — | — | — | — | — | — | — |
Corporate, International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.